Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BGB-B2033 Monotherapy in Advanced Hepatocellular Carcinoma
NCT07911683Phase 2Not yet recruiting
- Sponsor
- BeOne Medicines
- Start
- Nov 2026
- Primary completion
- Mar 2028
01
Overview
A Phase 2 trial of BGB-B2033 in hepatocellular carcinoma (HCC), sponsored by BeOne Medicines. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
BGB-B2033
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07911683.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07911683.